Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxychloroquine therapy in massive total doses without retinal toxicity.

M W Johnson, A K Vine

    American Journal of Ophthalmology
    |August 15, 1987
    PubMed
    Summary

    Hydroxychloroquine (HCQ) retinopathy risk was assessed. Even with massive cumulative doses exceeding 1,000 g, most patients showed no toxicity, though one on a higher daily dose exhibited early signs.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase transitions in a programmable quantum spin glass simulator.

    Science (New York, N.Y.)·2018
    Same author

    Psychedelics as Medicines: An Emerging New Paradigm.

    Clinical pharmacology and therapeutics·2016
    Same author

    Oviposition preference of the diamondback moth (Plutella xylostelld) unaffected by the presence of conspecific eggs orBacillus thuringiensis.

    Journal of chemical ecology·2013
    Same author

    Thermally assisted quantum annealing of a 16-qubit problem.

    Nature communications·2013
    Same author

    Traction-induced foveal damage predisposes eyes with pre-existing posterior vitreous detachment to idiopathic macular hole formation.

    Eye (London, England)·2012
    Same author

    Quantum annealing with manufactured spins.

    Nature·2011

    Area of Science:

    • Ophthalmology
    • Rheumatology
    • Pharmacology

    Background:

    • Hydroxychloroquine (HCQ) is widely used for autoimmune conditions.
    • Concerns exist regarding potential retinal toxicity with long-term HCQ use.
    • Understanding the dose-response relationship is crucial for patient safety.

    Purpose of the Study:

    • To evaluate the association between cumulative hydroxychloroquine dose and retinal toxicity.
    • To identify potential thresholds for HCQ-induced retinopathy.

    Main Methods:

    • Retrospective review of patient histories.
    • Inclusion criteria: cumulative HCQ dose > 1,000 g.
    • Assessment of retinal toxicity and daily dosage.

    Main Results:

    • Nine patients received massive cumulative HCQ doses (1,054–3,923 g).
    • No retinopathy was observed in these patients.
    • Eight patients on ≤400 mg/day showed no toxicity; one on 600 mg/day had preretinopathy.

    Conclusions:

    • High cumulative hydroxychloroquine doses may not invariably lead to retinopathy.
    • Lower daily doses appear safer, even with significant cumulative exposure.
    • Higher daily doses (e.g., 600 mg/day) may increase risk, warranting closer monitoring.

    Related Experiment Videos